The independent source for health policy research, polling, and news.
1,061 - 1,080 of 1,289 Results
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor鈥檚 office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
With the nation's opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned "the lion鈥檚 share" of their Medicare income exclusively from urine drug screens.
UnitedHealth, a health industry goliath, has its hand in doctors鈥 offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are 鈥榳annabes.鈥
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers 鈥 middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Patients flocked to researcher who ignored usual patient protections, as university claimed ignorance.
The costs of using a new class of cancer treatments include far more than the drug鈥檚 sticker price.
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
"If it gets signed by this governor, it's going to send shock waves throughout the country,鈥 one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
At a political rally in March, President Donald Trump said drug prices are 鈥渙utrageous鈥 and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
The company鈥檚 drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
听
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of 鈥渙rphan drugs鈥 while closing a loophole that allowed drugmakers to skip pediatric testing.
漏 2026 KFF